CYP2J8 Inhibitors
CYP2J8 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the CYP2J8 enzyme, a member of the cytochrome P450 superfamily. CYP2J8 is involved in the metabolism of a diverse array of substrates, including endogenous molecules such as fatty acids, eicosanoids, and other bioactive lipids, as well as exogenous compounds like certain pharmaceuticals and environmental toxins. The enzyme plays a crucial role in the oxidative metabolism of these substrates, catalyzing the insertion of an oxygen atom into the substrate molecule. This oxidation process typically enhances the solubility of lipophilic substrates, facilitating their subsequent metabolism, conjugation, or excretion from the body. CYP2J8 is particularly active in tissues such as the liver, heart, and kidneys, where it contributes to the regulation of lipid signaling pathways and the detoxification of various compounds.
Inhibitors of CYP2J8 are generally small molecules that bind to the enzyme's active site, preventing it from catalyzing the oxidation of its natural substrates. These inhibitors may function by occupying the substrate-binding pocket, thereby blocking access to the catalytic site, or by inducing conformational changes that decrease the enzyme's catalytic efficiency. The design and development of CYP2J8 inhibitors require a thorough understanding of the enzyme's structure, especially the regions involved in substrate recognition and catalysis. By inhibiting CYP2J8, researchers can explore the enzyme's specific role in metabolic pathways, particularly how its activity influences lipid metabolism and the processing of bioactive compounds. The study of CYP2J8 inhibitors is essential for understanding the enzyme's substrate specificity, its interactions with other metabolic enzymes, and its overall contribution to maintaining metabolic balance within the body. This research contributes to a broader understanding of the cytochrome P450 family's diverse functions, highlighting the critical role of these enzymes in the metabolism of both endogenous and exogenous molecules in biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluconazole | 86386-73-4 | sc-205698 sc-205698A | 500 mg 1 g | $54.00 $84.00 | 14 | |
Azole antifungal compound acting as an indirect inhibitor of CYP2J8. It disrupts the isomerase activity, impacting the linoleic acid metabolic process and contributing to the inhibition of the target protein within the cytoplasm. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Broad-spectrum antifungal agent known to inhibit CYP2J8. It hinders the monooxygenase activity, affecting the xenobiotic metabolic process and contributing to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
Terbinafine | 91161-71-6 | sc-338609 | 100 mg | $560.00 | 1 | |
Antifungal agent in research with inhibitory effects on CYP2J8. By interfering with the monooxygenase activity, it impacts the xenobiotic metabolic process and contributes to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
1-Aminobenzotriazole | 1614-12-6 | sc-200600 sc-200600A | 50 mg 100 mg | $61.00 $134.00 | 6 | |
Suicide inhibitor of cytochrome P450 enzymes, including CYP2J8. Irreversibly binds to the heme group, disrupting the isomerase activity and xenobiotic metabolic process, leading to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
Miconazole | 22916-47-8 | sc-204806 sc-204806A | 1 g 5 g | $66.00 $160.00 | 2 | |
Imidazole antifungal agent acting as an indirect inhibitor of CYP2J8. Through interference with the monooxygenase activity, it impacts the xenobiotic metabolic process, leading to indirect inhibition of the target protein within the cytoplasm. | ||||||
Clotrimazole | 23593-75-1 | sc-3583 sc-3583A | 100 mg 1 g | $42.00 $57.00 | 6 | |
Imidazole antifungal compound acting as an indirect inhibitor of CYP2J8. It interferes with the monooxygenase activity, impacting the xenobiotic metabolic process and leading to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
Triclosan | 3380-34-5 | sc-220326 sc-220326A | 10 g 100 g | $141.00 $408.00 | ||
Broad-spectrum antibacterial agent known to inhibit CYP2J8. Disrupts the monooxygenase activity, interfering with the xenobiotic metabolic process and contributing to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Selective serotonin reuptake inhibitor acting as an indirect inhibitor of CYP2J8. It disrupts the isomerase activity, impacting the xenobiotic metabolic process and contributing to the inhibition of the target protein within the cytoplasm. | ||||||
Econazole | 27220-47-9 | sc-279013 | 5 g | $240.00 | ||
Imidazole antifungal agent with inhibitory effects on CYP2J8. Interferes with the monooxygenase activity, impacting the xenobiotic metabolic process and contributing to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||
Ticlopidine Hydrochloride | 53885-35-1 | sc-205861 sc-205861A | 1 g 5 g | $32.00 $99.00 | 2 | |
Antiplatelet drug known to inhibit CYP2J8. Through its influence on the isomerase activity, it affects the xenobiotic metabolic process, leading to indirect inhibition of the target protein within intracellular membrane-bounded organelles. | ||||||